Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Polypharmacology Approaches against the Pseudomonas aeruginosa MvfR Regulon and Their Application in Blocking Virulence and Antibiotic Tolerance.

Maura D, Drees SL, Bandyopadhaya A, Kitao T, Negri M, Starkey M, Lesic B, Milot S, Déziel E, Zahler R, Pucci M, Felici A, Fetzner S, Lépine F, Rahme LG.

ACS Chem Biol. 2017 May 19;12(5):1435-1443. doi: 10.1021/acschembio.6b01139. Epub 2017 Apr 12.

PMID:
28379691
2.

Bioanalysis of Pseudomonas aeruginosa alkyl quinolone signalling molecules in infected mouse tissue using LC-MS/MS; and its application to a pharmacodynamic evaluation of MvfR inhibition.

Turnpenny P, Padfield A, Barton P, Teague J, Rahme LG, Pucci MJ, Zahler R, Rubio A.

J Pharm Biomed Anal. 2017 May 30;139:44-53. doi: 10.1016/j.jpba.2017.02.034. Epub 2017 Feb 28.

PMID:
28273650
3.

Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.

Shi Y, Li J, Kennedy LJ, Tao S, Hernández AS, Lai Z, Chen S, Wong H, Zhu J, Trehan A, Lim NK, Zhang H, Chen BC, Locke KT, O'Malley KM, Zhang L, Srivastava RA, Miao B, Meyers DS, Monshizadegan H, Search D, Grimm D, Zhang R, Harrity T, Kunselman LK, Cap M, Muckelbauer J, Chang C, Krystek SR, Li YX, Hosagrahara V, Zhang L, Kadiyala P, Xu C, Blanar MA, Zahler R, Mukherjee R, Cheng PT, Tino JA.

ACS Med Chem Lett. 2016 Apr 4;7(6):590-4. doi: 10.1021/acsmedchemlett.6b00033. eCollection 2016 Jun 9.

4.

Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARα/γ agonists.

Zhang H, Ding CZ, Lai Z, Chen SS, Devasthale P, Herpin T, Morton G, Qu F, Ryono D, Smirk R, Wang W, Wu S, Ye XX, Li YX, Apedo A, Farrelly D, Wang T, Gu L, Morgan N, Flynn N, Chu C, Kunselman L, Lippy J, Locke K, O'Malley K, Harrity T, Cap M, Zhang L, Hosagrahara V, Kadiyala P, Xu C, Doweyko AM, Zahler R, Hariharan N, Cheng PT.

Bioorg Med Chem Lett. 2015 Mar 15;25(6):1196-205. doi: 10.1016/j.bmcl.2015.01.066. Epub 2015 Feb 4.

PMID:
25686852
5.

Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).

Devasthale P, Wang Y, Wang W, Fevig J, Feng J, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Moulin F, Li YX, Zahler R, Kirby MS, Hamann LG.

J Med Chem. 2013 Sep 26;56(18):7343-57. doi: 10.1021/jm4008906. Epub 2013 Sep 9.

PMID:
23964740
6.

Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.

Bolton SA, Sutton JC, Anumula R, Bisacchi GS, Jacobson B, Slusarchyk WA, Treuner UD, Wu SC, Zhao G, Pi Z, Sheriff S, Smirk RA, Bisaha S, Cheney DL, Wei A, Schumacher WA, Hartl KS, Liu E, Zahler R, Seiler SM.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5239-43. doi: 10.1016/j.bmcl.2013.06.028. Epub 2013 Jun 20.

PMID:
23927973
7.

7-Oxopyrrolopyridine-derived DPP4 inhibitors-mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site.

Wang W, Devasthale P, Wang A, Harrity T, Egan D, Morgan N, Cap M, Fura A, Klei HE, Kish K, Weigelt C, Sun L, Levesque P, Li YX, Zahler R, Kirby MS, Hamann LG.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6646-51. doi: 10.1016/j.bmcl.2011.09.074. Epub 2011 Sep 24.

PMID:
21996520
8.

Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.

Meng W, Brigance RP, Chao HJ, Fura A, Harrity T, Marcinkeviciene J, O'Connor SP, Tamura JK, Xie D, Zhang Y, Klei HE, Kish K, Weigelt CA, Turdi H, Wang A, Zahler R, Kirby MS, Hamann LG.

J Med Chem. 2010 Aug 12;53(15):5620-8. doi: 10.1021/jm100634a.

PMID:
20684603
9.

Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.

Brigance RP, Meng W, Fura A, Harrity T, Wang A, Zahler R, Kirby MS, Hamann LG.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4395-8. doi: 10.1016/j.bmcl.2010.06.063. Epub 2010 Jun 15.

PMID:
20598534
10.

Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).

Li J, Kennedy LJ, Shi Y, Tao S, Ye XY, Chen SY, Wang Y, Hernández AS, Wang W, Devasthale PV, Chen S, Lai Z, Zhang H, Wu S, Smirk RA, Bolton SA, Ryono DE, Zhang H, Lim NK, Chen BC, Locke KT, O'Malley KM, Zhang L, Srivastava RA, Miao B, Meyers DS, Monshizadegan H, Search D, Grimm D, Zhang R, Harrity T, Kunselman LK, Cap M, Kadiyala P, Hosagrahara V, Zhang L, Xu C, Li YX, Muckelbauer JK, Chang C, An Y, Krystek SR, Blanar MA, Zahler R, Mukherjee R, Cheng PT, Tino JA.

J Med Chem. 2010 Apr 8;53(7):2854-64. doi: 10.1021/jm9016812.

PMID:
20218621
11.

N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation.

Nirschl AA, Zou Y, Krystek SR Jr, Sutton JC, Simpkins LM, Lupisella JA, Kuhns JE, Seethala R, Golla R, Sleph PG, Beehler BC, Grover GJ, Egan D, Fura A, Vyas VP, Li YX, Sack JS, Kish KF, An Y, Bryson JA, Gougoutas JZ, DiMarco J, Zahler R, Ostrowski J, Hamann LG.

J Med Chem. 2009 May 14;52(9):2794-8. doi: 10.1021/jm801583j.

PMID:
19351168
12.

Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.

Zhang H, Ryono DE, Devasthale P, Wang W, O'Malley K, Farrelly D, Gu L, Harrity T, Cap M, Chu C, Locke K, Zhang L, Lippy J, Kunselman L, Morgan N, Flynn N, Moore L, Hosagrahara V, Zhang L, Kadiyala P, Xu C, Doweyko AM, Bell A, Chang C, Muckelbauer J, Zahler R, Hariharan N, Cheng PT.

Bioorg Med Chem Lett. 2009 Mar 1;19(5):1451-6. doi: 10.1016/j.bmcl.2009.01.030. Epub 2009 Jan 15.

PMID:
19201606
13.

Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists.

Ye XY, Li YX, Farrelly D, Flynn N, Gu L, Locke KT, Lippy J, O'Malley K, Twamley C, Zhang L, Ryono DE, Zahler R, Hariharan N, Cheng PT.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3545-50. doi: 10.1016/j.bmcl.2008.05.014. Epub 2008 May 6.

PMID:
18511276
14.

Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

Wang H, Ruan Z, Li JJ, Simpkins LM, Smirk RA, Wu SC, Hutchins RD, Nirschl DS, Van Kirk K, Cooper CB, Sutton JC, Ma Z, Golla R, Seethala R, Salyan ME, Nayeem A, Krystek SR Jr, Sheriff S, Camac DM, Morin PE, Carpenter B, Robl JA, Zahler R, Gordon DA, Hamann LG.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3168-72. doi: 10.1016/j.bmcl.2008.04.069. Epub 2008 May 1.

PMID:
18485702
15.

(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.

Ahmad S, Madsen CS, Stein PD, Janovitz E, Huang C, Ngu K, Bisaha S, Kennedy LJ, Chen BC, Zhao R, Sitkoff D, Monshizadegan H, Yin X, Ryan CS, Zhang R, Giancarli M, Bird E, Chang M, Chen X, Setters R, Search D, Zhuang S, Nguyen-Tran V, Cuff CA, Harrity T, Darienzo CJ, Li T, Reeves RA, Blanar MA, Barrish JC, Zahler R, Robl JA.

J Med Chem. 2008 May 8;51(9):2722-33. doi: 10.1021/jm800001n. Epub 2008 Apr 15.

PMID:
18412317
16.

Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.

Wang W, Devasthale P, Farrelly D, Gu L, Harrity T, Cap M, Chu C, Kunselman L, Morgan N, Ponticiello R, Zebo R, Zhang L, Locke K, Lippy J, O'Malley K, Hosagrahara V, Zhang L, Kadiyala P, Chang C, Muckelbauer J, Doweyko AM, Zahler R, Ryono D, Hariharan N, Cheng PT.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1939-44. doi: 10.1016/j.bmcl.2008.01.126. Epub 2008 Feb 7.

PMID:
18291645
17.

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN.

J Med Chem. 2008 Mar 13;51(5):1145-9. doi: 10.1021/jm701272q. Epub 2008 Feb 9.

PMID:
18260618
18.

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.

Simpkins LM, Bolton S, Pi Z, Sutton JC, Kwon C, Zhao G, Magnin DR, Augeri DJ, Gungor T, Rotella DP, Sun Z, Liu Y, Slusarchyk WS, Marcinkeviciene J, Robertson JG, Wang A, Robl JA, Atwal KS, Zahler RL, Parker RA, Kirby MS, Hamann LG.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6476-80. Epub 2007 Oct 1.

PMID:
17937986
19.

Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.

Shi Y, Sitkoff D, Zhang J, Han W, Hu Z, Stein PD, Wang Y, Kennedy LJ, O'Connor SP, Ahmad S, Liu EC, Seiler SM, Lam PY, Robl JA, Macor JE, Atwal KS, Zahler R.

Bioorg Med Chem Lett. 2007 Nov 1;17(21):5952-8. Epub 2007 Aug 21.

PMID:
17855089
20.

Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications.

Li JJ, Sutton JC, Nirschl A, Zou Y, Wang H, Sun C, Pi Z, Johnson R, Krystek SR Jr, Seethala R, Golla R, Sleph PG, Beehler BC, Grover GJ, Fura A, Vyas VP, Li CY, Gougoutas JZ, Galella MA, Zahler R, Ostrowski J, Hamann LG.

J Med Chem. 2007 Jun 28;50(13):3015-25. Epub 2007 Jun 7.

PMID:
17552509
21.

Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators.

Hamann LG, Manfredi MC, Sun C, Krystek SR Jr, Huang Y, Bi Y, Augeri DJ, Wang T, Zou Y, Betebenner DA, Fura A, Seethala R, Golla R, Kuhns JE, Lupisella JA, Darienzo CJ, Custer LL, Price JL, Johnson JM, Biller SA, Zahler R, Ostrowski J.

Bioorg Med Chem Lett. 2007 Apr 1;17(7):1860-4. Epub 2007 Jan 27.

PMID:
17292608
22.

Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.

Atwal KS, O'Neil SV, Ahmad S, Doweyko L, Kirby M, Dorso CR, Chandrasena G, Chen BC, Zhao R, Zahler R.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4796-9. Epub 2006 Jul 25.

PMID:
16870436
23.

Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.

Shi Y, Zhang J, Stein PD, Shi M, O'Connor SP, Bisaha SN, Li C, Atwal KS, Bisacchi GS, Sitkoff D, Pudzianowski AT, Liu EC, Hartl KS, Seiler SM, Youssef S, Steinbacher TE, Schumacher WA, Rendina AR, Bozarth JM, Peterson TL, Zhang G, Zahler R.

Bioorg Med Chem Lett. 2005 Dec 15;15(24):5453-8. Epub 2005 Oct 5. Erratum in: Bioorg Med Chem Lett. 2006 Mar 1;16(5):1449.

PMID:
16213711
24.

Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase.

Weinstein DS, Liu W, Gu Z, Langevine C, Ngu K, Fadnis L, Combs DW, Sitkoff D, Ahmad S, Zhuang S, Chen X, Wang FL, Loughney DA, Atwal KS, Zahler R, Macor JE, Madsen CS, Murugesan N.

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1435-40.

PMID:
15713402
25.

Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.

Murugesan N, Gu Z, Fadnis L, Tellew JE, Baska RA, Yang Y, Beyer SM, Monshizadegan H, Dickinson KE, Valentine MT, Humphreys WG, Lan SJ, Ewing WR, Carlson KE, Kowala MC, Zahler R, Macor JE.

J Med Chem. 2005 Jan 13;48(1):171-9.

PMID:
15634011
26.

Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.

Sutton JC, Bolton SA, Davis ME, Hartl KS, Jacobson B, Mathur A, Ogletree ML, Slusarchyk WA, Zahler R, Seiler SM, Bisacchi GS.

Bioorg Med Chem Lett. 2004 May 3;14(9):2233-9.

PMID:
15081015
27.

Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase.

Bisacchi GS, Slusarchyk WA, Bolton SA, Hartl KS, Jacobs G, Mathur A, Meng W, Ogletree ML, Pi Z, Sutton JC, Treuner U, Zahler R, Zhao G, Seiler SM.

Bioorg Med Chem Lett. 2004 May 3;14(9):2227-31.

PMID:
15081014
28.

Synthesis of potent and highly selective inhibitors of human tryptase.

Slusarchyk WA, Bolton SA, Hartl KS, Huang MH, Jacobs G, Meng W, Ogletree ML, Pi Z, Schumacher WA, Seiler SM, Sutton JC, Treuner U, Zahler R, Zhao G, Bisacchi GS.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3235-8.

PMID:
12372541
29.

Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.

Sutton JC, Bolton SA, Hartl KS, Huang MH, Jacobs G, Meng W, Ogletree ML, Pi Z, Schumacher WA, Seiler SM, Slusarchyk WA, Treuner U, Zahler R, Zhao G, Bisacchi GS.

Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33.

PMID:
12372540
30.

Phenotypical features of long Q-T syndrome in transgenic mice expressing human Na-K-ATPase alpha(3)-isoform in hearts.

O'Brien SE, Apkon M, Berul CI, Patel HT, Saupe K, Spindler M, Ingwall JS, Zahler R.

Am J Physiol Heart Circ Physiol. 2000 Nov;279(5):H2133-42.

31.

Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus.

Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ.

Antimicrob Agents Chemother. 1999 Jan;43(1):190-3.

32.

Transgenic mice expressing human alpha 3 Na,K-ATPase isoform in heart.

Zahler R, Lufburrow M, Manor M, Shenoy R, Fornasari D, Romana M, Sun W.

Ann N Y Acad Sci. 1997 Nov 3;834:687-9. No abstract available.

PMID:
9405893
33.

Sodium kinetics of Na,K-ATPase alpha isoforms in intact transfected HeLa cells.

Zahler R, Zhang ZT, Manor M, Boron WF.

J Gen Physiol. 1997 Aug;110(2):201-13.

34.

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus.

Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ.

Antimicrob Agents Chemother. 1997 Jul;41(7):1444-8.

35.

Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.

Chen P, Cheng PT, Alam M, Beyer BD, Bisacchi GS, Dejneka T, Evans AJ, Greytok JA, Hermsmeier MA, Humphreys WG, Jacobs GA, Kocy O, Lin PF, Lis KA, Marella MA, Ryono DE, Sheaffer AK, Spergel SH, Sun CQ, Tino JA, Vite G, Colonno RJ, Zahler R, Barrish JC.

J Med Chem. 1996 May 10;39(10):1991-2007.

PMID:
8642558
36.

Na, K-ATPase isoform gene expression in normal and hypertrophied dog heart.

Zahler R, Gilmore-Hebert M, Sun W, Benz EJ.

Basic Res Cardiol. 1996 May-Jun;91(3):256-66.

PMID:
8831945
37.

The alpha3 isoform protein of the Na+, K(+)-ATPase is associated with the sites of cardiac and neuromuscular impulse transmission.

Zahler R, Sun W, Ardito T, Zhang ZT, Kocsis JD, Kashgarian M.

Circ Res. 1996 May;78(5):870-9.

PMID:
8620608
38.

Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.

Leftheris K, Kline T, Vite GD, Cho YH, Bhide RS, Patel DV, Patel MM, Schmidt RJ, Weller HN, Andahazy ML, Carboni JM, Gullo-Brown JL, Lee FY, Ricca C, Rose WC, Yan N, Barbacid M, Hunt JT, Meyers CA, Seizinger BR, Zahler R, Manne V.

J Med Chem. 1996 Jan 5;39(1):224-36.

PMID:
8568812
39.

Na-K-ATPase alpha-isoform expression in heart and vascular endothelia: cellular and developmental regulation.

Zahler R, Sun W, Ardito T, Kashgarian M.

Am J Physiol. 1996 Jan;270(1 Pt 1):C361-71.

PMID:
8772464
40.

Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.

Manne V, Yan N, Carboni JM, Tuomari AV, Ricca CS, Brown JG, Andahazy ML, Schmidt RJ, Patel D, Zahler R, et al.

Oncogene. 1995 May 4;10(9):1763-79.

PMID:
7753553
41.

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.

Patick AK, Rose R, Greytok J, Bechtold CM, Hermsmeier MA, Chen PT, Barrish JC, Zahler R, Colonno RJ, Lin PF.

J Virol. 1995 Apr;69(4):2148-52.

42.

Phosphinyl acid-based bisubstrate analog inhibitors of Ras farnesyl protein transferase.

Patel DV, Gordon EM, Schmidt RJ, Weller HN, Young MG, Zahler R, Barbacid M, Carboni JM, Gullo-Brown JL, Hunihan L, et al.

J Med Chem. 1995 Feb 3;38(3):435-42.

PMID:
7853336
43.

Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease.

Bechtold CM, Patick AK, Alam M, Greytok J, Tino JA, Chen P, Gordon E, Ahmad S, Barrish JC, Zahler R, et al.

Antimicrob Agents Chemother. 1995 Feb;39(2):374-9.

44.

Expression of alpha isoforms of the Na,K-ATPase in human heart.

Zahler R, Gilmore-Hebert M, Baldwin JC, Franco K, Benz EJ Jr.

Biochim Biophys Acta. 1993 Jul 4;1149(2):189-94.

PMID:
8391840
45.

Lactic acidosis: effect of treatment on intracellular pH and energetics in living rat heart.

Zahler R, Barrett E, Majumdar S, Greene R, Gore JC.

Am J Physiol. 1992 May;262(5 Pt 2):H1572-8.

PMID:
1590462
46.

Estimation of heart mitochondrial creatine kinase flux using magnetization transfer NMR spectroscopy.

Zahler R, Ingwall JS.

Am J Physiol. 1992 Apr;262(4 Pt 2):H1022-8.

PMID:
1566885
47.

The cardiac conduction system in the rat expresses the alpha 2 and alpha 3 isoforms of the Na+,K(+)-ATPase.

Zahler R, Brines M, Kashgarian M, Benz EJ Jr, Gilmore-Hebert M.

Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):99-103.

48.

NMR determination of myocardial pH in vivo: separation of tissue inorganic phosphate from blood 2,3-DPG.

Zahler R, Majumdar S, Frederick B, Laughlin M, Barrett E, Gore JC.

Magn Reson Med. 1991 Feb;17(2):368-78.

PMID:
1648160
49.

Heterogeneous signal intensity in magnetic resonance images of hypertrophied left ventricular myocardium.

Zahler R, Chelmow D, Gore J, Wilkens K, Pope C, Sostman HD, Meese R, Negro-Vilar R, Herfkens RJ, Wackers FJ, et al.

Magn Reson Imaging. 1989 Sep-Oct;7(5):517-28.

PMID:
2532699
50.

The versatile monobactam family: manipulation of intrinsic activity and in vivo efficacy via N-1 activating group modification.

Koster WH, Bonner DP, Zahler R.

J Chemother. 1989 Jul;1(4 Suppl):116-8. No abstract available.

PMID:
16312331

Supplemental Content

Loading ...
Support Center